Capecitabine trials for Colorectal cancer

All Capecitabine trials · All Colorectal cancer trials

Phase breakdown

Recruiting trials studying Capecitabine for Colorectal cancer

• A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
  NCT06839105 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer
  NCT07113275 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer
  NCT06885385 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
  NCT06493760 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer
  NCT07239466 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer
  NCT05093907 · Phase: Phase 1, Phase 2 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
  NCT06825624 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Adaptive Radiation in Anal Cancer
  NCT05838391 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
  NCT06324357 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 105 locations
• CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer
  NCT05585814 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
  NCT07281768 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
  NCT06540326 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
  NCT06282445 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery
  NCT06780787 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer
  NCT05914389 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• JS212 Combination Therapies in Metastatic Colorectal Cancer
  NCT07503756 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
  NCT04808323 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer
  NCT06368141 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer
  NCT06017583 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
  NCT06205485 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 113 locations
• Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer
  NCT06204094 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Organ Preservation in Rectal AdenoCa Using Hypofractionated Pelvic RT(Hypo-OPRA)
  NCT06991465 · Phase: Phase 2 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 1 location
• PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
  NCT05236972 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer
  NCT05136326 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
  NCT06949111 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer
  NCT07562659 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer
  NCT07562711 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
  NCT07474103 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
  NCT06065371 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
  NCT05731726 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
  NCT04703101 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)
  NCT06455124 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma
  NCT07692152 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
  NCT05489211 · Phase: Phase 2 · Ages: 18 Years to 130 Years · Sex: All (male and female) · 96 locations
• Study to Evaluate the Use of Capecitabine in Monotherapy and in Combination With Oxaliplatin in Elderly Patients as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer.
  NCT06888843 · Phase: Phase 2 · Ages: 70 Years to 90 Years · Sex: All (male and female) · 1 location
• Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
  NCT05803382 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
  NCT05628038 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma
  NCT06266832 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
  NCT07407465 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations

Common questions

How many trials study Capecitabine for Colorectal cancer?

39 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.